Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Erika Ryst & Ann Childress. (2023) An updated safety review of the current drugs for managing ADHD in children. Expert Opinion on Drug Safety 22:11, pages 1025-1040.
Read now
Read now
Ann Childress, Robert Sottile & Sherine Khanbijian. (2023) Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients. Expert Review of Neurotherapeutics 23:11, pages 945-953.
Read now
Read now
C. Brendan Montano, W. Clay Jackson, Denise Vanacore & Richard Weisler. (2023) Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression. Postgraduate Medicine 135:5, pages 449-465.
Read now
Read now
Ann Childress & Shelby Burton. (2022) Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder. Expert Opinion on Drug Metabolism & Toxicology 18:6, pages 357-366.
Read now
Read now
Articles from other publishers (42)
Haley Raible & Manoranjan S. D’Souza. (2023) Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents. Annals of Pharmacotherapy, pages 106002802311632.
Crossref
Crossref
Edmund J.S. Sonuga‐Barke, Stephen P. Becker, Sven Bölte, Francisco Xavier Castellanos, Barbara Franke, Jeffrey H. Newcorn, Joel T. Nigg, Luis Augusto Rohde & Emily Simonoff. (2022)
Annual Research Review: Perspectives on progress in
ADHD
science – from characterization to cause
. Journal of Child Psychology and Psychiatry 64:4, pages 506-532.
Crossref
Crossref
Kelsey K. Wiggs, Tanya E. Froehlich & Stephen P. Becker. (2023) Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research. CNS Drugs 37:4, pages 293-304.
Crossref
Crossref
Stephen V. Faraone, Roberto Gomeni, Joseph T. Hull, Gregory D. Busse, Brendan Lujan, Jonathan Rubin & Azmi Nasser. (2023)
Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree
®
): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder
. Brain and Behavior 13:4.
Crossref
Crossref
Hueng-Chuen Fan, Kuo-Liang Chiang, Kuang-Hsi Chang, Chuan-Mu Chen & Jeng-Dau Tsai. (2023) Epilepsy and Attention Deficit Hyperactivity Disorder: Connection, Chance, and Challenges. International Journal of Molecular Sciences 24:6, pages 5270.
Crossref
Crossref
Stephen V. Faraone, Roberto Gomeni, Joseph T. Hull, Gregory D. Busse, Zare Melyan, Jonathan Rubin & Azmi Nasser. (2021) A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder. European Child & Adolescent Psychiatry 32:3, pages 491-499.
Crossref
Crossref
Alessio Bellato, John Perna, Preethi S. Ganapathy, Marco Solmi, Andrea Zampieri, Samuele Cortese & Stephen V. Faraone. (2022) Association between ADHD and vision problems. A systematic review and meta-analysis. Molecular Psychiatry 28:1, pages 410-422.
Crossref
Crossref
Victoria A. Nazarova, Aleksandr V. Sokolov, Vladimir N. Chubarev, Vadim V. Tarasov & Helgi B. Schiöth. (2022) Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Frontiers in Pharmacology 13.
Crossref
Crossref
Azmi Nasser, Roberto Gomeni, Zhao Wang, Joseph T. Hull, Gregory D. Busse, Zare Melyan, Maurizio Fava, Welton O'Neal & Jonathan Rubin. (2022) The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder. British Journal of Clinical Pharmacology 88:11, pages 4828-4838.
Crossref
Crossref
Christopher L Robinson, Katelyn Parker, Saurabh Kataria, Evan Downs, Rajesh Supra, Alan D. Kaye, Omar Viswanath & Ivan Urits. (2022) Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder. Health Psychology Research 10:3.
Crossref
Crossref
Xin-Peng Xu, Wei Wang, Song Wan & Chun-Feng Xiao. (2022) Convergence mechanism of mindfulness intervention in treating attention deficit hyperactivity disorder: Clues from current evidence. World Journal of Clinical Cases 10:26, pages 9219-9227.
Crossref
Crossref
AK Chigome, JC Meyer & N Schellack. (2022) The management of attention-deficit hyperactivity disorder in children: updated 2022. South African General Practitioner 3:4, pages 121-131.
Crossref
Crossref
Mohamed Adil Shah Khoodoruth, Sami Ouanes & Yasser Saeed Khan. (2022) A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder. Research in Developmental Disabilities 128, pages 104275.
Crossref
Crossref
Azmi Nasser, Joseph T. Hull, Soumya A. Chaturvedi, Tesfaye Liranso, Oyinkansola Odebo, Alisa R. Kosheleff, Nicholas Fry, Andrew J. Cutler, Jonathan Rubin, Stefan Schwabe & Ann Childress. (2022) A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs 36:8, pages 897-915.
Crossref
Crossref
Gizem Kayki-Mutlu, Zinnet Sevval Aksoyalp, Leszek Wojnowski & Martin C. Michel. (2022) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn-Schmiedeberg's Archives of Pharmacology 395:8, pages 867-885.
Crossref
Crossref
Hannah W Haddad, Paul B. Hankey, Jimin Ko, Zahaan Eswani, Pravjit Bhatti, Amber N. Edinoff, Adam M. Kaye & Alan D. Kaye. (2022) Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update. Health Psychology Research 10:2.
Crossref
Crossref
Brayden Kameg. (2022)
Viloxazine ER (Qelbree
®
): A New Non-Stimulant Option in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder
. Journal of Psychosocial Nursing and Mental Health Services 60:7, pages 7-9.
Crossref
Crossref
Deepan Singh. 2022. Neuro-behavioral Manifestations of Prader-Willi Syndrome. Neuro-behavioral Manifestations of Prader-Willi Syndrome
154
170
.
Keith Mather & Michelle Condren. (2022) Extended-Release Viloxazine for Children and Adolescents With Attention Deficit Hyperactivity Disorder. The Journal of Pediatric Pharmacology and Therapeutics 27:5, pages 409-414.
Crossref
Crossref
Andrew J. Cutler, Gregory W. Mattingly, Rakesh Jain & Welton O’Neal. (2020) Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectrums 27:2, pages 199-207.
Crossref
Crossref
Xiaohong Huang, Jiaying Hu, Haining Peng & Heng-wei Cheng. (2022) Embryonic Exposure to Tryptophan Yields Bullying Victimization via Reprogramming the Microbiota-Gut-Brain Axis in a Chicken Model. Nutrients 14:3, pages 661.
Crossref
Crossref
Konstantin Mechler, Tobias Banaschewski, Sarah Hohmann & Alexander Häge. (2022) Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacology & Therapeutics 230, pages 107940.
Crossref
Crossref
Mahesh Kumar Balasundaram & Alok Singh. (2022) Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication. Drugs & Therapy Perspectives 38:2, pages 77-83.
Crossref
Crossref
Alok Singh, Mahesh Kumar Balasundaram & Abhishek Singh. (2022) Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Journal of Central Nervous System Disease 14, pages 117957352210925.
Crossref
Crossref
Sabahat Hafeez, Javeria Saquib & Nazuk Eraj Qureshi. (2022) Viloxazine: A new miracle drug for attention deficit hyperactivity disorder (ADHD) or just another non-stimulant?. Asian Journal of Psychiatry 67, pages 102948.
Crossref
Crossref
Pozzi Marco, Mauri Maddalena, Bertella Silvana, Gatti Erika & Nobile Maria. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
256
285
.
David J. Heal, Jane Gosden & Sharon L. Smith. 2022. New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder. New Discoveries in the Behavioral Neuroscience of Attention-Deficit Hyperactivity Disorder
79
126
.
Amber N. Edinoff, Haseeb A. Akuly, John H. Wagner, Megan A. Boudreaux, Leah A. Kaplan, Shadman Yusuf, Elisa E. Neuchat, Elyse M. Cornett, Andrea G. Boyer, Adam M. Kaye & Alan D. Kaye. (2021) Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder. Frontiers in Psychiatry 12.
Crossref
Crossref
Azmi Nasser, Roberto Gomeni, Zhao Wang, Alisa R. Kosheleff, Lanyi Xie, Lilian W. Adeojo & Stefan Schwabe. (2021) Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder. The Journal of Clinical Pharmacology 61:12, pages 1626-1637.
Crossref
Crossref
Stephen V. Faraone, Roberto Gomeni, Joseph T. Hull, Gregory D. Busse, Zare Melyan, Jonathan Rubin & Azmi Nasser. (2021) Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials. Pediatric Drugs 23:6, pages 583-589.
Crossref
Crossref
Zhao Wang, Alisa R. Kosheleff, Lilian W. Adeojo, Oyinkansola Odebo, Toyin Adewole, Peibing Qin, Vladimir Maletic, Stefan Schwabe & Azmi Nasser. (2021) Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults. Clinical Pharmacology in Drug Development 10:11, pages 1365-1374.
Crossref
Crossref
Ahmed Naguy, Awadhesh P. Singh Solanki & Bibi Alamiri. (2021) Newly FDA-approved psychotropic agents-a recap. Asian Journal of Psychiatry 64, pages 102786.
Crossref
Crossref
Samuele Cortese, Jeffrey H. Newcorn & David Coghill. (2021) A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). CNS Drugs 35:10, pages 1035-1051.
Crossref
Crossref
Azmi Nasser, Alisa R. Kosheleff, Joseph T. Hull, Tesfaye Liranso, Peibing Qin, Gregory D. Busse, Maurizio Fava, Vladimir Maletic, Jonathan Rubin & Frank Lopez. (2021) Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder. International Journal of Clinical Practice 75:8.
Crossref
Crossref
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T. Hull, Gregory D. Busse, Fatima Chowdhry, Andrew J. Cutler, Nandita Joshi Jones, Robert L. Findling & Stefan Schwabe. (2021) A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology 41:4, pages 370-380.
Crossref
Crossref
Yvette N. Lamb. (2021) Viloxazine: Pediatric First Approval. Pediatric Drugs 23:4, pages 403-409.
Crossref
Crossref
Robert L. Findling, Shawn A. Candler, Azmi F. Nasser, Stefan Schwabe, Chungping Yu, Jennie Garcia-Olivares, Welton O’Neal & Jeffrey H. Newcorn. (2021) Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs 35:6, pages 643-653.
Crossref
Crossref
Azmi NasserAlisa R. KosheleffJoseph T. HullTesfaye LiransoPeibing QinGregory D. BusseWelton O'NealMaurizio FavaStephen V. FaraoneJonathan Rubin. (2021) Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 31:3, pages 214-226.
Crossref
Crossref
Gregory W. Mattingly & Joel Young. (2021) A clinician’s guide for navigating the world of attention deficit hyperactivity disorder medications. CNS Spectrums 26:2, pages 104-114.
Crossref
Crossref
Shamia L. Faison, Nicholas Fry, Toyin Adewole, Oyinkansola Odebo, Zhao Wang, Vladimir Maletic & Azmi Nasser. (2021) Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. Journal of Clinical Psychopharmacology 41:2, pages 155-162.
Crossref
Crossref
Stephen V. Faraone, Roberto Gomeni, Joseph T. Hull, Gregory D. Busse, Zare Melyan, Welton O'Neal, Jonathan Rubin & Azmi Nasser. (2021) Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Research 296, pages 113664.
Crossref
Crossref
Shamia L. Faison, Nicholas Fry, Toyin Adewole, Oyinkansola Odebo, Stefan Schwabe, Zhao Wang, Vladimir Maletic & Azmi Nasser. (2020) Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults. Clinical Drug Investigation 41:2, pages 149-159.
Crossref
Crossref